论文部分内容阅读
目的:探讨地喹氯铵联合紫杉醇注射液对神经胶质瘤患者血清IL-6、Th17细胞水平及临床疗效的影响。方法:回顾性研究我院神经胶质瘤患者60例,根据电脑生成的随机数字表将所有患者随机分为实验组与对照组,每组各30例,对照组患者给予地喹氯铵进行治疗,实验组患者在对照组的基础上给予紫杉醇注射液。比较治疗前后两组患者血清IL-6,Th17细胞水平,并对两组患者不良反应发生率及临床总有效率进行统计。结果:与治疗前相比,两组患者治疗后的血清IL-6、Th17细胞水平均显著降低(P<0.05);且与对照组相比,实验组患者血清IL-6、Th17细胞水平均较低(P<0.05)。与对照组相比,实验组患者的不良反应发生率较低(P<0.05);临床总有效率较高(P<0.05)。结论:地喹氯铵联合紫杉醇注射液能够显著提高神经胶质瘤患者临床疗效,降低不良反应发生率,其机制可能与降低血清IL-6及Th17细胞水平有关。
OBJECTIVE: To investigate the effect of deconochlorammonium and paclitaxel injection on the serum levels of IL-6 and Th17 cells in patients with glioma and the clinical efficacy. Methods: A retrospective study of 60 patients with glioma in our hospital, all patients were randomly divided into experimental group and control group according to random number table generated by computer, 30 patients in each group, the control group were treated with dequalinium chloride Patients in the experimental group were given paclitaxel injection on the basis of the control group. The serum levels of IL-6 and Th17 in both groups were compared before and after treatment, and the incidence of adverse reactions and the total clinical efficiency were compared between the two groups. Results: Compared with those before treatment, the levels of IL-6 and Th17 in both groups were significantly lower than those before treatment (P <0.05). Compared with the control group, the levels of IL-6 and Th17 Lower (P <0.05). Compared with the control group, the incidence of adverse reactions in the experimental group was lower (P <0.05), and the total effective rate was higher (P <0.05). Conclusion: Diquitin combined with paclitaxel injection can significantly improve the clinical efficacy of glioma patients and reduce the incidence of adverse reactions, the mechanism may be related to the reduction of serum IL-6 and Th17 cell levels.